| Name | Title | Contact Details |
|---|
ADC Therapeutics is a commercial-stage biotechnology company improving the lives of those affected by cancer with our next-generation, targeted antibody drug conjugates (ADCs). With an ADC platform validated by the FDA approval of ZYNLONTA® and a deep understanding of the oncology treatment landscape, we are working to address significant unmet medical needs and improve outcomes for those with difficult-to-treat hematological cancers and solid tumors. Founded in 2011, ADC Therapeutics is based in Lausanne, Switzerland, with operations in London (R&D), New Jersey (Clinical and Commercial), and the San Francisco Bay Area (CMC). Our highly skilled global team is committed to confronting cancer with the full potential of our science, bringing unique, targeted therapies and hope to patients and their families.
Pionyr Immuntherapeutics (formerly Precision Immune Inc.) is developing cancer immunotherapies that target the tumor microenvironment to enhance the body`s antitumor immunity. The company is exploiting novel target discovery and antibody generation platform technologies to create the next generation of immuno-oncology therapeutics. The company`s approach, Myeloid Tuning™, is designed to enhance the immune system`s anti-tumor response by altering the cellular infiltrate of the tumor microenvironment with high specificity.
Antibody Solutions is a Sunnyvale, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Lung Therapeutics pursues innovative treatments for underserved, life-threatening lung conditions.